About Dapagliflozin (Amorphous) API
Therapeutic CategoryAnti-Diabetic
CAS Number
461432-26-8
API Technology
Synthetic
Dose Form
Oral Solids
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Canada DMF, Korea DMF, Russia DMF
Mechanism of Action
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion
Indication
FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Related APIs
Dapagliflozin (PG Solvate Monohydrate)
Anti-Diabetic
Glimepiride
Anti-Diabetic
Linagliptin
Anti-Diabetic
Liraglutide
Anti-Diabetic
Pioglitazone Hydrochloride
Anti-Diabetic
Sitagliptin Hydrochloride
Anti-Diabetic
Dapagliflozin (Amorphous)
Anti-Diabetic
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
FAQs
Dapagliflozin Amorphous API is used to treat type 2 diabetes, chronic kidney disease, and heart failure.
-
Lowers blood glucose, promotes weight loss, reduces blood pressure, and decreases cardiovascular risks.
-
Handle with care, avoid inhalation, ingestion, and contact with eyes and skin. Use protective equipment.
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.